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ABSTRACT
This study aimed to evaluate the clinical pharmacist interventions in reducing drug-related problems 
(DRPs) in childhood acute lymphoblastic leukemia (ALL) patients in the Tangerang District General 
Hospital, Banten, Indonesia. This study used a prospective analysis of patients with a pre-post design 
between January-March 2017. The Pharmaceutical Care Network Europe (PCNE) (V6.2) pre-post 
study system was used to identify the DRPs of 138 patients. The Pharmacist interventions were 
addressed to physicians, patients, and other health professions to determine the effectiveness of 
pharmacist interventions before and after the intervention. The number of identified DRPs was 177 
problems and the identified types of DRP was 164 types. The pharmacist interventions significantly 
decreased the DRPs from 177 to 10 DRPs (p<0.05) and type of DRPs from 164 to 10 types of DRPs 
(p<0.05). Risk factors for nutritional status, type of ALL, comorbidities, number of drug items, and 
type of treatments did not significantly affect (p>0.05) to the decreased of the number and type 
of DRPs. Clinical pharmacist interventions able to reduce the number and type of DRPs and can 
improve treatment outcomes in childhood ALL.
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INTRODUCTION
WHO data reported the prevalence of childhood cancers 
is accounting for 0.5% to 4.6% of all cancers. The total 
incidence rates of childhood cancer vary between 50 and 
200 per million children worldwide. In general, leukemia 
constitutes about a third of all cancer in childhood (WHO, 
2017). A number of 11,000 cases of childhood cancer 
have been reported each year in Indonesia and 1957 
cases of acute lymphoblastic leukemia (ALL) in children 
occurred in 15 hospitals in Indonesia around 2007-2012, 
in which approximately 650 cases developed in Jakarta 
(Ministry of Health of the Republic of Indonesia, 2015).
Most of the childhood cancer cases appear without 
specific symptoms causing a delay in the diagnosis 
of cancer. Inaccurate diagnosis of cancer, inadequate 
equipment and medication in hospitals lead to disease 
complications. The lack of cancer-related knowledge in 
primary care providers also renders the effectiveness of 
cancer treatment (Ministry of Health of the Republic of 
Indonesia, 2015).
The incidence of childhood leukemia under the age of 15 
years is about 4-4,5/100,000 children per year while the 
highest frequency occurs at the age of 2-5 years (Basic 
Health Research, 2013). The onset of acute lymphoblastic 
leukemia (ALL) usually develop unexpectedly and can 
lead to death if not treated properly. The appropriate 
treatment increased the life expectancy of patients 
significantly as many as 96-99% of children could 
achieve full remission, and 50-60% of patients had a 
good prognosis (Dipiro et al., 2011 and Sabatine, 2014).
During the year 2010-2013, ALL is a disease with the 
highest incidence and mortality in Indonesia (Ministry 
of Health the Republic of Indonesia, 2015). The 
previous study reported that all leukemia patients in 
Yogyakarta, Indonesia had 35% refused treatment, 23% 
experienced treatment-related deaths, 22% suffered 
adverse conditions or relapsed, and 20% recovered from 
illness (Mostert et al., 2010). That study illustrates the 
current general situation in Indonesia (The Oncology-
Hematology Work Coordination Unit, Association of 
Indonesian Pediatricians, 2013). 
Although the drug plays an important role in the healing 
and prevention of illness, most patients develop drug-
related problems (DRPs). DRPs are conditions that 
potentially affects the desired outcome of the therapy. 
DRPs evolve immediately after administration of drug 
therapy and might affect the patient’s clinical condition 
that is associated with patient morbidity and mortality 
(Pharmaceutical Care Network Europe, 2010). Many 
studies showed the consequences of DRPs, which 
include additional doctor visits, long-term treatments, 
hospitalization, polypharmacy and emergency room care 
(Baena et al., 2006). 
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A study of DRPs in a children’s ward at Zewditu 
Memorial Referral Hospital, Addis Ababa, Ethiopia 
showed the incidence of DRPs was 31.6%. Dose-related 
problems had a notable percentage about 45 (42.5%) 
of all DRPs. Drug-drug interactions (DDIs) occurred 
about 41 (38.7%), and undesirable drug reactions were 9 
(8.5%) (Biarra et al., 2017).
The role of pharmacists in pharmaceutical care for 
pediatric patients is to plan an optimal drug therapy by 
considering pathophysiological changes, drug efficacy, 
and specific toxicity. Therefore, pharmacists play a vital 
role in detecting, preventing and overcoming drug-
related problems (Ministry of Health of the Republic 
of Indonesia, 2009). This study was conducted to 
evaluate the effect of clinical pharmacist’s intervention 
in reducing the DRPs in pediatric acute lymphoblastic 
leukemia treated with chemotherapy at referral hospitals 
in Tangerang, Indonesia.
METHODS
This study was conducted in child ward of Tangerang 
District General Hospital and carried out as prospective 
design, a pre-post design before and after pharmacist’s 
intervention over the period from January to March 2017. 
The study was approved by the Ethics Committee of the 
Faculty of Medicine University of Indonesia (No: 948 / 
UN2.F1 / ETIK / 2016).  The sampling was conducted by 
purposive sampling and the selected sample was based 
on inclusion criteria, i.e., patients who have DRPs aged 
one month to <18 years old and undergo hospitalization 
or one day care chemotherapy. The exclusion criteria 
were relapsed childhood ALL patients and patients with 
incomplete medical record data. 
The drug therapy details, laboratory parameters and 
demographic details of all inpatients were prospectively 
reviewed by a clinical pharmacist. During ward 
rounds, drug and dose selection, drug regimens and 
patients’ drug use patterns were evaluated in order 
to identify DRPs as per Version 6.2 of the PCNE 
classification system. Pharmacist’s interventions 
consisted of reporting and discussing identified DRPs 
during interviews with various recipients, including 
pediatrician, patients, pharmaceutical logistics clerks, 
nurses and nutritionists. The type of intervention 
was classified as either independent (i.e. specifically 
tailored to an individual recipient) or concurrent (i.e. 
provided to several or all recipients at the same time). 
It is important to note that each DRP could be targeted 
with more than one intervention. After the interventions, 
the pharmacist continued monitoring the patient until 
discharge, conducting further interventions as necessary 
for any subsequent DRPs. The overall number of clinical 
problems and the overall number and subtypes of DRPs 
before and after the intervention were calculated for 
every patient. Data were analyzed using the Statistical 
Package for the Social Sciences (SPSS), Version 23.0 
(IBM Corp., Armonk, New York, USA). A Wilcoxon 
signed rank test was used to assess the differences 
between pre- and post-intervention DRPs. A Chi-squared 
test was used to assess the relationship between DRPs 
and risk factors such as nutritional status, type of ALL, 
comorbidities, the number of drug items and type of care. 
RESULTS AND DISCUSSION
Demographic and Clinical Data of Patients
A total of 138 patients had met the inclusion requirements 
and had been recruited for the study, consisted of female 
(52.9%) and male (47.1%). Patients were the age at 
>5-10-years-old (44.2%), yet they mostly suffered at 
the age of 4-years-old (17.4%). It is consistent with 
the previous studies that indicated the incidence rates 
of leukemia in children occurred at the age of 2-5 
years (Widiaskara et al., 2010; Ministry of Health 
of the Republic of Indonesia, 2011). Data on patient 
characteristics were shown in Table 1. 
This study showed that the number of high risks (HR) 
ALL was more dominant (77.5%). It might be due to 
the childhood ALL patients coming to the provincial 
referral hospital in more severe conditions due to the 
long initial diagnosis and referral process on the way up 
to the hospital. There is a possibility of an increased in 
cancer cells malignancy that often leads to a condition 
of hyperleukocytosis (leukocyte count > 50,000/
mm3). In contrast, other studies reported the number of 
standard risks (SR) childhood ALL is higher than in-
patients at HR (Latamu et al., 2016). Another study at 
Cipto Mangunkusumo Hospital, Jakarta, Indonesia, also 
showed that 64.3% of the patients were SR childhood 
ALL (Permatasari et al., 2009).
Our results also found that the most common types of 
comorbidities were thrombocytopenia, anemia and, 
diarrhea. It is similar with the characteristic clinical 
symptoms of pediatric ALL, anemia (<7 g/dL) at 43%, 
normochromic normocytic, thrombocytopenia (severe, 
< 20,000 cells/mm3) at 28% of cases (Dipiro et al., 
2014). Diarrhea is one of the infections that can be 
found in childhood ALL patients. The most common 
cause of diarrhea is excessive intestinal motility, either 
due to local irritation of the intestinal wall caused by 
bacterial and viral infection or due to the emotional 
stress. One of the main consequences of Leukemia is 
the inability of the immune system to defend the body 
from invasion of foreign matter. In leukemia, white 
blood cell counts can reach as high as 500,000/mm3, 
compared with a normal count of 7,000/mm3. However, 
because most cells are abnormal or immature, they are 
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Table 1. Basic demographic and clinical data of patients (n=138 patients)
Characteristic Category Total (%)
Age 1-5 year-old
>5-10 year-old
>10-15 year-old
>15 -18 year-old
47 (34.1)
61 (44.2)
28 (20.3)
2 (1.4)
Sex Male
Female
73 (52.9)
65 (47.1)
Nutritional status Good nutrition
Malnutrition 
132 (96.6)
6 (4.4)
ALL type Standard risk
High risk
31 (22.5)
107 (77.5)
Comorbidity 1-3
>3
134 (97.1)
4 (2.9)
Drug used item 1-5
>5
116 (84.1)
22 (15.9)
Type of care One-day care chemotherapy
Inpatient 
112 (81.16)
26 (18.84)
not capable of performing their defense functions. As a 
result, infection or severe bleeding is the most frequent 
cause of death in leukemia patients. Bacteria/viruses 
can easily invade people with immunosuppression. The 
notorious cause of diarrhea is due to irritation from a 
virus or bacterial infection in the distal bowel or colon 
(Guyton and  Hall, 2007). Besides of that, diarrhea may 
result from damage of gastrointestinal mucosal cells 
caused by chemotherapy. Antineoplastic drugs and 
antimetabolite groups, especially methotrexate, also 
have side effects on the digestive tract, bone marrow and 
oral mucosa (Boussios et al., 2012). Stomatitis, diarrhea, 
thrombocytopenia, leukopenia or any sudden decline in 
leukocyte and thrombocyte counts indicates of treatment 
discontinuation. It is done to prevent the fatal ulceration 
of the gastrointestinal tract, infections, and hemorrhages 
(Nafraldi, 2008). 
Treatment of Acute Lymphoblastic Leukemia 
Patients
The total number of drugs given to childhood ALL 
patients in this study was 422 items consisting of 
44 types of drugs. Methotrexate either intrathecal or 
intravenously was commonly used at 31.3% due to the 
most patients (81.2%) were undergo a maintenance 
phase of chemotherapy which is given methotrexate 
tablet once a week. The use of drugs was followed by 
6-mercaptopurine (29.1%) and vincristine (3.1%). Most 
of them received one to five items (84.1%), and the 
others received more than five items (15.9%).
The study was found that 96.6% of childhood ALL has 
good nutritional status. Nutrition status data was taken 
from the medical records that have been assessed by 
the hospital’s nutrition department. Malnutrition has 
a significant effect on ALL treatment outcomes. There 
are several reasons for the decrease in nutrient intake, 
one of them is the presence of cytokines such as alpha 
necrosis tumors that cause anorexia. The effects of 
pro-inflammatory cytokines have been investigated as 
the cause of various metabolic phenomena in cancer. 
Other causes of the reduced intakes of nutrients that 
causing anorexia and gastrointestinal effects are the 
high doses of chemotherapy drugs and radiotherapy that 
leads to mucosal damaged or toxicity. Moreover, dose-
enhancing patterns, continuous infusion (versus bolus 
dose), and combination chemotherapy treatment also 
elevate the side effects. High doses of chemotherapy 
often cause painful oral mucositis, which reduces the 
nutritional intake of several weeks. The treatment effects 
on gastrointestinal including esophagitis and enteritis 
with malabsorption and diarrhea increased sensitivity 
to bitterness, resulting in reduced the nutritional intake 
and difficulty of oral supplementation (The Oncology-
Hematology Work Coordination Unit-Association of 
Indonesian Pediatricians, 2013; Mostert et al., 2010).
Identification of DRPs
Identification of DRPs was performed according to 
PCNE classification system version 6.2 2010. A total of 
177 DRPs were found, which 91.57% were actual DRPs 
and the remaining 8.43% were potential. The mean DRP 
per patient was 1.28 while the type of DRP was 164 types. 
The average type of DRP that occurs per patient was 1.19. 
The number of DRPs before pharmacist intervention was 
shown in Figure 1 and the description sub-domain of 
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Figure 1. Number of DRPs of patients in the study before pharmacist’s intervention (n=177 DRPs)
DRPs was shown in Figure 2. We also identified types 
of DRPs with 61.02% were patient’s dissatisfaction with 
the therapy they have received, 29.3% was non-allergic 
effects, and 8.48% was the not optimal effects of drugs. 
DRPs that occurred include the effectiveness of therapy 
(9.04%), adverse drug reactions (ADRs) (29.94%), 
treatment costs (0%) and other problems (61.02%). The 
most common causes of DRPs were associated with 
pharmaceutical logistics in which prescription drugs 
were not available (62.1%), adverse events occurred in 
patients (23.2%), and drug interactions (5.6%). Data on 
number of DRPs and difference of DRPs before and after 
receiving pharmacist intervention characteristics were 
shown in Table 2. 
The unavailable drug was methotrexate tablets used by 
childhood ALL patients in the maintenance phase, even 
though DPRs of methotrexate was the highest incidence 
Figure 2. Sub-domain of DRPs of patients in the study before pharmacist’s intervention (n = 177 DRPs)
because it has been used in every phase of HR and SR 
ALL chemotherapy. The duration of chemotherapy also 
a significant cause of DRPs. In the maintenance phase, 
chemotherapy regimens used methotrexate tablet once a 
week for SR. The maintenance phase started at week 13 
and ended at week 110, while at HR started in 18 weeks 
and ended at week 118. Therefore, to overcome the 
problems, we gave counseling on the non-availability 
of methotrexate tablets and replaced the treatment with 
alternatives using methotrexate intravenous.
The effectiveness of drug was evaluated by comparing 
whether the dosage, method of use, interval, and 
duration of use were suitable with the indication for the 
childhood ALL patients in the literature or chemotherapy 
protocol, without monitoring the blood levels of the 
drug. The determination of DRPs in this study had 
several limitations among other studies, for example 
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Table 2. Evaluation of decreased number of DRP after receiving pharmacist intervention 
January-March 2017
Primary 
problem Code Problems
Amount of DRPs 
pre-intervention 
Amount of 
DRPs post-
intervention
Treatment 
effectiveness
P 1.1 No effect of drug treatment/ therapy failure 0 (0%) 0 (0%)
P 1.2 Effect of drug treatment not optimal 15 (8.48%) 2 (1.13%)
P 1.3 Wrong effect of drug treatment 0 (0%) 0 (0%)
P 1.4 Untreated indication 1 (0.66%) 0 (0%)
Total 16 (9.04%) 2 (1.13%)
Adverse 
reactions
P 2.1 Adverse drug event (non-allergic) 28 (15.82%) 6 (3.39%)
P 2.2 Adverse drug event (allergic) 7 (3.95%) 0 (0%)
P 2.3 Toxic adverse drug-event 18 (10.12%) 2 (1.13%)
Total 53 (29.94%) 8 (4.52%)
Treatment 
costs
P 3.1 Drug treatment more costly than necessary 0 (0%) 0 (0%)
P 3.2 Unnecessary drug-treatment 0 (0%) 0 (0%)
Total 0 (0%) 0 (0%)
Others
P 4.1 Patient dissatisfied with therapy despite 
optimal clinical and economic treatment 
outcomes 
108 (61.02%) 0 (0%)
P.4.2 Unclear problem/complaint. Further 
clarification necessary
0 (0%) 0 (0%)
Total 108 (61.02%) 0 (0%)
Total of DRP Found                             177 10 
Difference of DRP before and after receiving pharmacist 
intervention 
            167 (94.35%)
there is no examination of allergy with skin pricks test 
or measurement of specific immunoglobulin E (IgE) 
levels in the blood to decide if the patient has allergic 
adverse drug reactions (ADRs). Determination of 
patients experiencing allergic ADRs could be measured 
if there are signs and symptoms of a real allergy. For 
example, red bumps appear in the skin that repeatedly 
occur, eyelids and swollen lips, shortness of breath that 
is not caused by other diseases, dry skin, redness as 
well as itching recurring in typical locations such as the 
cheek area, elbow folds, behind the knee, and based on 
the results of a specialist skin examination. This study 
also did not examine the levels of drugs in the blood to 
evaluate potentially/suffering from toxic effects. The 
determination of potentially/suffering patient’s toxic 
effects was evaluated by checking whether the patient 
receives drugs that are at the risk of organ toxicity 
according to the literature and performing laboratory 
investigation of related organ function.
Evaluation of Pharmacist Interventions
In this study, most of the clinical pharmacist interventions 
had been well received by health professions and 
patients (94.9%) in Tangerang District General Hospital. 
The target of dominant interventions was physicians, 
patients, nurses, and the pharmaceutical department 
which amounted to 93.6% of 177 DRPs. Clinical 
pharmacist interventions were performed to reduce the 
incidence of DRPs and have a positive effect on drug 
therapy services in childhood ALL patients, but not all 
interventions were accepted and performed in this study. 
A total of nine DRPs were not intervened because four 
of them were not intervened by pharmacists, merely by 
doctors. The other two DRPs were not intervened because 
no electrolyte examination was performed to monitor 
the risk of hypocalcemia caused by the interaction of 
dexamethasone (corticosteroid) with furosemide (loop 
diuretic). Three interventions on DRPs were also not 
accepted by doctors because two interventions could 
not be performed due to unavailability of facilities and 
infrastructure for a liver biopsy to monitor the risk of 
methotrexate hepatotoxicity after accumulation dose 
of 4 g followed by the increase of 1.5 g doses. Another 
one intervention was not accepted regarding the clinical 
condition of patients suffering from hypocalcemia due 
to Lysis Syndrome Tumors (TLS). The physician was 
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worried if the intravenous calcium given, the TLS would 
be worsening.
Bivariate analysis was conducted using the Wilcoxon 
Sign Rank test to determine the effect of clinical 
pharmacist intervention on the number and type of DRPs 
before and after the intervention. The results showed that 
there was a notable change in the number of DRPs with 
the mean value before the intervention was decreased 
from 1.28 to 0.07 after the intervention. Moreover, 
the reduction of mean value in the type of DRPs also 
occurred at 1.19 before the intervention to 0.07 after 
the intervention. Evaluation of decreased number and 
type of DRP after receiving pharmacist intervention was 
shown in Table 2. 
The Fisher exact bivariate analysis was used to identify 
correlations between nutritional status, type of ALL, 
comorbidity, the number of drug items, and type of 
care that could decrease the number and type of DRPs 
of childhood ALL before and after clinical pharmacist 
intervention. The change of number and type of DRPs 
with risk factors of patients after receiving pharmacist 
intervention was shown in Table 3. The results showed 
that the number of drugs used and the type of care 
significantly affected the decrease in the type of DRPs 
(p<0.05). Several previous studies showed the amount of 
drug administered to patients is an important risk factor 
for the occurrence of DRPs (Ibrahim N et al., 2013; 
PCNE, 2010; Rashed AN et al., 2014; Rashed AN et al., 
2012). More complex drug therapy due to the presence 
of disease complications leads to a higher risk of DRPs 
such as side effects, drug interactions, medication errors, 
and noncompliance. It occurs because in this case the 
more drugs will be consumed. 
Logistic regression multivariate analysis was conducted 
to see the most dominant risk factors for the decrease 
type of DRPs. The test results showed a none significant 
difference of risk factor effect on the decrease type of 
DRPs (p>0.05). This study reported that the decrease in 
the number and type of DRPs in childhood ALL patients 
in Tangerang District General Hospital is due to the 
success of the pharmacist intervention in preventing 
potential DRPs and completing the actual DRPs.
CONCLUSION
This prospective study found that DRPs among 
childhood ALL patients were significantly reduced 
following a clinical pharmacist intervention amount to 
94.35%. The number of DRPs identified with childhood 
ALL inpatients and patients who underwent one day care 
chemotherapy at the Tangerang District General Hospital 
was 177 problems which consisted of 164 types of 
problems. DRPs that occurred include the effectiveness 
of therapy (9.04%), adverse drug reactions (ADRs) 
(29.94%), treatment costs (0%) and other problems 
(61.02%).  The risk factors of nutritional status, type of 
LLA, number of comorbidities, number of drug items 
and type of treatment did not give a significant effect to 
reduce the number and type of DRPs (p>0.05). These 
Table 3. Change of number and type of DRPs with risk factors of patients after receiving pharmacist intervention 
(n=138 patients)
Risk Factor Category 
Change in number of 
DRP
Total p value
Change in type of DRP
Total P value
Decreased 
(%)
Constant/ 
Increased 
(%)
Decreased 
(%)
Constant/ 
Increased 
(%)
Nutritional 
status
Good
Malnutrition
131 (99.2)
1 (0.8)
6 (100)
0 (0)
137
1 0.957
131 (99.2)
6 (100)
1 (0.8)
0 (0)
132
6
0.085
ALL type SR
HR
31 (100)
106 (99.3)
0 (0)
1 (0.9)
31
107
0.775 31 (100)
105 (98.1)
0 (0)
2 (1.9)
31
107
0.600
Comorbidity 1-3
> 3
133 (99.3)
4 (100)
1 (0.7)
0 (0)
134
4
0,971 132 (98.5)
4 (100)
2 (1.5)
0 (0)
134
4
0.943
Number of 
drugs used
1-5
>5
116 (100)
21 (95.5)
0 (0)
1 (4.5)
116
22
0.159 116 (100)
20 (90.9)
0 (0)
2 (9.1)
116
22
0.024*
Type of care ODC
Inpatient
112 (100)
25 (96.2)
0 (0)
1 (3.8)
112
26
0.118 112 (100)
24 (92.3)
0 (0)
2 (7.7)
112
26
0.034*
SR = standard risk, HR = high risk, ODC = One-day Care Chemotherapy, *statistically significant (p<0.05)
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findings indicate that a pharmacist intervention can 
optimize therapy of childhood ALL patients.
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